je.st
news
Home
› Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
2016-06-01 06:09:24| drugdiscoveryonline Home Page
Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), recently announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA (olaparib) in patients with advanced solid tumors
Tags: with
trial
combination
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||